Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BECAME Study: Booster BNT162b2 in Kidney Transplant Recipients
NCT04961229Phase 4Unknown
- Start
- Oct 2021
- Primary completion
- Feb 2022
- Modality
- Vaccines & Immunotherapeutics, Lipid-based Nanoparticles, mRNA Therapeutics
01
Overview
Phase 4, randomised, open-label trial of tozinameran in coronavirus disease 2019 (COVID-19) (3 arms). Primary endpoint: anti-spike protein titer above 50 AU/ml at 2 weeks. Status: unknown.
02
Drugs
tozinameran
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT04961229.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04961229.